Literature DB >> 20440681

Myxoma virus: propagation, purification, quantification, and storage.

Sherin E Smallwood1, Masmudur M Rahman, Dorothy W Smith, Grant McFadden.   

Abstract

Myxoma virus (MYXV) is a member of the Poxviridae family and prototype for the genus Leporipoxvirus. It is pathogenic only for European rabbits, in which it causes the lethal disease myxomatosis, and two North American species, in which it causes a less severe disease. MYXV replicates exclusively in the cytoplasm of the host cell. Although not infectious in humans, its genome encodes proteins that can interfere with or modulate host defense mechanisms; it is able to productively infect a number of human cancer cell lines, but not normal human cells, and has also been shown to increase survival time in mouse models of human glioma. These characteristics suggest that MYXV could be a viable therapeutic agent, e.g., in anti-inflammatory or anti-immune therapy, or as an oncolytic agent. MYXV is also an excellent model for poxvirus biology, pathogenesis, and host tropism studies. It is easily propagated in a number of cell lines, including adherent cells and suspension cultures, and minimal purification is required to provide a stock for in vivo and in vitro studies.

Entities:  

Mesh:

Year:  2010        PMID: 20440681      PMCID: PMC2901999          DOI: 10.1002/9780471729259.mc14a01s17

Source DB:  PubMed          Journal:  Curr Protoc Microbiol


  14 in total

1.  The complete DNA sequence of myxoma virus.

Authors:  C Cameron; S Hota-Mitchell; L Chen; J Barrett; J X Cao; C Macaulay; D Willer; D Evans; G McFadden
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

Review 2.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 3.  Growing poxviruses and determining virus titer.

Authors:  Girish J Kotwal; Melissa-Rose Abrahams
Journal:  Methods Mol Biol       Date:  2004

Review 4.  Secreted immunomodulatory viral proteins as novel biotherapeutics.

Authors:  Alexandra Lucas; Grant McFadden
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

5.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.

Authors:  L Liu; A Lalani; E Dai; B Seet; C Macauley; R Singh; L Fan; G McFadden; A Lucas
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Authors:  Marianne M Stanford; John W Barrett; Steven H Nazarian; Steven Werden; Grant McFadden
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 7.  Myxoma virus in the European rabbit: interactions between the virus and its susceptible host.

Authors:  Marianne M Stanford; Steven J Werden; Grant McFadden
Journal:  Vet Res       Date:  2007-02-13       Impact factor: 3.683

8.  Host-specificity of myxoma virus: Pathogenesis of South American and North American strains of myxoma virus in two North American lagomorph species.

Authors:  L Silvers; D Barnard; F Knowlton; B Inglis; A Labudovic; M K Holland; P A Janssens; B H van Leeuwen; P J Kerr
Journal:  Vet Microbiol       Date:  2009-09-25       Impact factor: 3.293

Review 9.  Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.

Authors:  Marianne M Stanford; Grant McFadden
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

10.  Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.

Authors:  M Kim; G J Madlambayan; M M Rahman; S E Smallwood; A M Meacham; K Hosaka; E W Scott; C R Cogle; G McFadden
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528

View more
  45 in total

1.  Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Authors:  Rohann J M Correa; Monica Komar; Jessica G K Tong; Milani Sivapragasam; Masmudur M Rahman; Grant McFadden; Gabriel E Dimattia; Trevor G Shepherd
Journal:  Gynecol Oncol       Date:  2012-02-01       Impact factor: 5.482

3.  Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Authors:  Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Blood       Date:  2015-04-22       Impact factor: 22.113

4.  Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Authors:  Franz J Zemp; Brienne A McKenzie; Xueqing Lun; Karlyne M Reilly; Grant McFadden; V Wee Yong; Peter A Forsyth
Journal:  Cancer Res       Date:  2014-10-21       Impact factor: 12.701

5.  Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.

Authors:  Mee Y Bartee; Katherine M Dunlap; Eric Bartee
Journal:  Cancer Res       Date:  2017-03-17       Impact factor: 12.701

6.  Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence.

Authors:  Stephanie A Lamb; Masmudur M Rahman; Grant McFadden
Journal:  Virology       Date:  2014-07-26       Impact factor: 3.616

7.  Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.

Authors:  Gerard J Madlambayan; Eric Bartee; Manbok Kim; Masmudur M Rahman; Amy Meacham; Edward W Scott; Grant McFadden; Christopher R Cogle
Journal:  Leuk Res       Date:  2012-02-17       Impact factor: 3.156

8.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

10.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.